DB:30S

Stock Analysis Report

Executive Summary

Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Saniona's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 30S's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.4%

30S

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

-25.1%

30S

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 30S underperformed the German Biotechs industry which returned -12.7% over the past year.

Return vs Market: 30S underperformed the German Market which returned -20.6% over the past year.


Shareholder returns

30SIndustryMarket
7 Day6.4%-0.7%-0.6%
30 Day-11.2%-12.1%-20.0%
90 Day-21.0%-22.3%-26.3%
1 Year-23.0%-25.1%-13.0%-13.2%-18.6%-20.9%
3 Yearn/a14.5%13.2%-19.0%-25.8%
5 Yearn/a-9.5%-11.8%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is Saniona's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Saniona undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 30S (€1.93) is trading below our estimate of fair value (€9.33)

Significantly Below Fair Value: 30S is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 30S is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 30S is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 30S's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 30S is overvalued based on its PB Ratio (10.4x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Saniona forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

60.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 30S is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 30S is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 30S is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 30S's revenue (52.3% per year) is forecast to grow faster than the German market (4% per year).

High Growth Revenue: 30S's revenue (52.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 30S's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Saniona performed over the past 5 years?

-40.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 30S is currently unprofitable.

Growing Profit Margin: 30S is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 30S is unprofitable, and losses have increased over the past 5 years at a rate of -40.4% per year.

Accelerating Growth: Unable to compare 30S's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 30S is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 30S has a negative Return on Equity (-129.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Saniona's financial position?


Financial Position Analysis

Short Term Liabilities: 30S's short term assets (SEK53.9M) exceed its short term liabilities (SEK35.4M).

Long Term Liabilities: 30S's short term assets (SEK53.9M) exceed its long term liabilities (SEK2.1M).


Debt to Equity History and Analysis

Debt Level: 30S is debt free.

Reducing Debt: 30S had no debt 5 years ago.


Balance Sheet

Inventory Level: 30S has a low level of unsold assets or inventory.

Debt Coverage by Assets: 30S's debt is not covered by short term assets (assets are -39.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 30S has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 30S has less than a year of cash runway if free cash flow continues to reduce at historical rates of -36.8% each year


Next Steps

Dividend

What is Saniona's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 30S's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 30S's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 30S's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 30S's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 30S's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Jørgen Drejer (64yo)

0.083

Tenure

kr1,687,000

Compensation

Mr. Jørgen Drejer, Ph.D., serves as Deputy Chief Executive Officer at Saniona AB (publ) since March 24, 2020 and also serves as its Chief Scientific Officer. He founded Saniona AB (Alternate name-Aniona) i ...


CEO Compensation Analysis

Compensation vs Market: Jørgen's total compensation ($USD165.74K) is below average for companies of similar size in the German market ($USD431.53K).

Compensation vs Earnings: Jørgen's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jørgen Drejer
Co-Founder0.083yrkr1.69m7.97% SEK4.6m
Claus Bræstrup
Co-Founder & Director6.25yrsno data2.5% SEK1.4m
Rami Levin
President & CEO0.25yrno datano data
Anita Milland
Interim CFO & Head of Investor Relations0.083yrno datano data
Karin Nielsen
Vice President of Operations and Director of In Vivo Pharmacology4.08yrsno datano data

0.3yrs

Average Tenure

Experienced Management: 30S's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jørgen Drejer
Co-Founder0.083yrkr1.69m7.97% SEK4.6m
Claus Bræstrup
Co-Founder & Director6.25yrsno data2.5% SEK1.4m
J. deBethizy
Chairman of the Board2.25yrskr1.15mno data
Carl Sundberg
Independent Director4.58yrskr145.00kno data
Edward Saltzman
Director0.92yrno datano data
Anna Ljung
Independent Director2.25yrskr184.00kno data

3.4yrs

Average Tenure

64yo

Average Age

Experienced Board: 30S's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.


Top Shareholders

Company Information

Saniona AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Saniona AB (publ)
  • Ticker: 30S
  • Exchange: DB
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr629.428m
  • Listing Market Cap: kr57.317m
  • Shares outstanding: 29.41m
  • Website: https://www.saniona.com

Number of Employees


Location

  • Saniona AB (publ)
  • Baltorpvej 154
  • Ballerup
  • Capital Region of Denmark
  • 2750
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SANIONOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKApr 2014
0RQJLSE (London Stock Exchange)YesShare CapitalGBSEKApr 2014
30SDB (Deutsche Boerse AG)YesShare CapitalDEEURApr 2014

Biography

Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company’s products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trials to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase II clinical trial for tremor and spinocerebellar ataxia. It is also developing SAN711 for chronic itching and neuropathic pain; Boehringer Ingelheim program for schizophrenia; IK program for inflammatory bowel diseases; Nicotinic-a6 program for parkinson’s diseases; Kv7 program for pain, epilepsy, and urinary incontinence; and SAN903 for autoimmune disorders. Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/03 22:59
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.